News & Sentiment
CrowdStrike stock rises after bullish analyst calls
CrowdStrike CRWD shares gained about 1.1% in trading on Tuesday after receiving fresh support from Wall Street, with Loop Capital initiating coverage on the cybersecurity company with a Buy rating and Cantor Fitzgerald reiterating its bullish stance. Loop Capital analyst Yun Kim assigned a $230...
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
982 articles
📰
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
Pacific Biosciences of California (PACB) reached $1.39 at the closing of the latest trading day, reflecting a +2.21% change compared to its last...
📰
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates
Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of +33.33% and +5.86%, respectively, for the quarter ended June 2026. Do the...
📰
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates
Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of +33.33% and +5.86%, respectively, for the quarter ended June 2026. Do the...
📰
Chemed (CHE) Tops Q2 Earnings and Revenue Estimates
Chemed (CHE) delivered earnings and revenue surprises of +9.19% and +1.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues...
📰
Why Cardinal Health (CAH) Outpaced the Stock Market Today
In the most recent trading session, Cardinal Health (CAH) closed at $232.51, indicating a +1.38% shift from the previous trading day.
📰
Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of +15.15% and +2.50%, respectively, for the quarter ended June 2026. Do the...
📰
Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of +15.15% and +2.50%, respectively, for the quarter ended June 2026. Do the...
📰
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $490.39, moving +2.38% from the previous trading session.
📰
Why Opko Health Stock Surged by 33% on Tuesday
It posted a beat-and-raise second quarter.
📰
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.
📰
CVS Health (CVS) Laps the Stock Market: Here's Why
CVS Health (CVS) closed the most recent trading day at $109.34, moving +2.12% from the previous trading session.
These 3 Companies Reported Record Results and Raised Guidance
Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking...
📰
Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case
The stock looks like a high-risk, high-reward play.
📰
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market MarketWatch
📰
Incyte Corporation (NASDAQ: INCY) lifts H1 2026 profit on drug sales and Vega deal - Stock Titan
Incyte Corporation (NASDAQ: INCY) lifts H1 2026 profit on drug sales and Vega deal Stock Titan
📰
3 Powerful AI Stocks Poised for the Next Massive Shift
AI's next winners may emerge from an overlooked part of the market. See how three software companies are turning proprietary expertise into a...
📰
This Healthcare Leader Just Made a Bet on Artificial Intelligence (AI): Time to Buy the Stock?
Bristol Myers keeps making moves to establish a strong foundation for the future.
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
ECL stock rises pre-market after earnings and revenues beat estimates, as pricing, volume growth and core-business demand lift organic sales.
Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
ECL stock rises pre-market after earnings and revenues beat estimates, as pricing, volume growth and core-business demand lift organic sales.
Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
ECL stock rises pre-market after earnings and revenues beat estimates, as pricing, volume growth and core-business demand lift organic sales.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?
BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion...
Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?
BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion...
Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?
BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion...
📰
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
The company isn't resting on its laurels.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1...
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1...
📰
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside
These stocks have market caps below $5 billion, but they could be much more valuable in the future.
Central Garden Expands Europe Pet Business With TRIXIE Acquisition
CENT is expanding into Europe through the TRIXIE acquisition, strengthening its global pet platform and international growth strategy.
IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised
IQVIA's Q2 earnings beat estimates as record R&D bookings, broad-based growth and stronger demand support a raised 2026 outlook.
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?
Supernus (SUPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the...
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get...